RYTM News and Press, Rhythm Pharmaceuticals Inc. From 01/09/23

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

Belite Bio (NASDAQ: BLTE) , TransMedics Group (NASDAQ: TMDX) and Rhythm Pharmaceuticals (NASDAQ: RYTM) set themselves apart over the past year with triple-digit share price gains. Each of the healthcare companies is developing something unique, whether it be finding trea...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

Summary Rhythm Pharmaceuticals is planning to get approvals for setmelanotide in an incremental fashion. Each new approval in a rare disease will add to the topline. Existing approved indications have shown a decent launch. Rhythm Pharmaceuticals, Inc. ( RYTM ) is up 1...

The following slide deck was published by Rhythm Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Rhythm Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation

BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc . (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathwa...

-- Health Canada accepts for review new drug submission for setmelanotide for the treatment of obesity and control of hunger in BBS and biallelic POMC, PCSK1 and LEPR deficiencies -- BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercia...

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Chien - ...

Rhythm Pharmaceuticals press release ( NASDAQ: RYTM ): Q3 GAAP EPS of -$0.79 beats by $0.22 . Revenue of $4.28M (+319.6% Y/Y) misses by $0.48M . cash, cash equivalents and short-term investments were approximately $347.8 million, For further details see: ...

-- Previously disclosed data demonstrated statistically significant and clinically meaningful reductions in weight and hunger in patients with Bardet-Biedl syndrome -- BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharma...